We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $1.01B
1-Year Est. Return 29.84%
This Fund
S&P 500
This Quarter Est. Return
+16.83%
1 Year Est. Return
+29.84%
3 Year Est. Return
+144%
5 Year Est. Return
+76.57%
10 Year Est. Return
+1,417.6%
AUM
$2.49B
AUM Growth
+$21.6M
Cap. Flow
+$155M
Cap. Flow %
6.21%
Top 10 Hldgs %
58.42%
Holding
119
New
16
Increased
22
Reduced
16
Closed
17

Top Buys

Rank Stock Value
1
MORF
Morphic Holding, Inc. Common Stock
MORF
+$27.6M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$23.7M
3
GBT
Global Blood Therapeutics, Inc.
GBT
+$18.2M
4
MDCO
Medicines Co
MDCO
+$16M
5
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
+$14.8M

Top Sells

Rank Stock Value
1
NVDA icon
NVIDIA
NVDA
+$37M
2
AVTR icon
Avantor
AVTR
+$16.9M
3
Z icon
Zillow
Z
+$13.9M
4
BPMC
Blueprint Medicines
BPMC
+$13M
5
HTHT icon
Huazhu Hotels Group
HTHT
+$12.7M

Sector Composition

Rank Sector Weight
1 Healthcare 49.17%
2 Consumer Discretionary 26.12%
3 Technology 2.9%
4 Communication Services 0.91%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INCY icon
26
CALL
Incyte
INCY
$25.5B
$18.6M 0.74%
250,000
– –
SLDB icon
27
Solid Biosciences
SLDB
$802M
$17.6M 0.7%
113,333
+33,333
+42% +$3.77M
GBT
28
DELISTED
Global Blood Therapeutics, Inc.
GBT
$17M 0.68%
+350,000
New +$18.2M
DCPH
29
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$17M 0.68%
+500,000
New +$14.8M
BABA icon
30
CALL
Alibaba
BABA
$277B
$16.7M 0.67%
100,000
-100,000
-50% -$17.2M
CYCN icon
31
Cyclerion Therapeutics
CYCN
$15M
$16.5M 0.66%
68,079
– –
MRTX
32
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$15.6M 0.62%
200,000
+50,000
+33% +$4.69M
EPZM
33
DELISTED
Epizyme, Inc
EPZM
$15.5M 0.62%
1,500,000
-150,000
-9% -$1.89M
UBER icon
34
Uber
UBER
$144B
$15.2M 0.61%
500,000
– –
TPTX
35
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
$15M 0.6%
400,000
+200,000
+100% +$8.71M
ASND icon
36
Ascendis Pharma A/S
ASND
$16.6B
$14.4M 0.58%
150,000
– –
DRNA
37
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$14.4M 0.58%
1,000,000
– –
AAL icon
38
CALL
American Airlines Group
AAL
$9.96B
$13.5M 0.54%
500,000
– –
AGIO icon
39
Agios Pharmaceuticals
AGIO
$2.09B
$13M 0.52%
400,000
-100,000
-20% -$4.14M
IOVA icon
40
Iovance Biotherapeutics
IOVA
$2.07B
$12.7M 0.51%
700,000
– –
REAL icon
41
The RealReal
REAL
$1.45B
$12.6M 0.51%
565,000
+545,000
+2,725% +$11M
TCDA
42
DELISTED
Tricida, Inc. Common Stock
TCDA
$11.1M 0.45%
360,000
– –
NKTR icon
43
CALL
Nektar Therapeutics
NKTR
$2.31B
$10.9M 0.44%
40,000
+33,333
+500% +$12.2M
STNE icon
44
StoneCo
STNE
$2.65B
$10.4M 0.42%
300,000
– –
YMAB
45
DELISTED
Y-mAbs Therapeutics
YMAB
$10.4M 0.42%
400,000
– –
XNCR icon
46
Xencor
XNCR
$1.46B
$10.1M 0.41%
300,000
+25,000
+9% +$998K
DLPH
47
CALL
DELISTED
Delphi Technologies PLC Ordinary Shares
DLPH
$10.1M 0.4%
+750,000
New +$11.9M
FIS icon
48
Fidelity National Information Services
FIS
$23.9B
$9.96M 0.4%
+75,000
New +$9.96M
BOLD
49
DELISTED
Audentes Therapeutics, Inc
BOLD
$9.83M 0.39%
350,000
– –
AXDX
50
DELISTED
Accelerate Diagnostics
AXDX
$9.29M 0.37%
50,000
+5,000
+11% +$966K
1
2
3 4 5

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $1.01B AUM 47.99% 1-Year Est. Return
GA
GRS Advisors Chicago, Illinois $1.01B AUM 13.12% 1-Year Est. Return
EPAM
Euro Pacific Asset Management Dorado, Puerto Rico $1.01B AUM 79.26% 1-Year Est. Return
WA
Wealth Alliance Mellville, New York $1.01B AUM 19.71% 1-Year Est. Return
CT
Coastline Trust Providence, Rhode Island $1.01B AUM 22.57% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return
PIM
Provident Investment Management Novi, Michigan $1.01B AUM 9.4% 1-Year Est. Return
MAM
Melqart Asset Management London, United Kingdom $1.01B AUM 84.85% 1-Year Est. Return

Artal Group's Q3 2019 Portfolio in Review

As of Q3 2019, Artal Group held 119 positions worth $2.49B, up 0.87% from $2.47B the previous quarter. Its ten largest holdings account for 58% of the portfolio.

Artal Group deployed $155M of net new capital in Q3 2019, opening 16 new positions and adding to 22 existing holdings. Its largest new stake was Global Blood Therapeutics, Inc.: 350,000 shares worth $17M.

By sector, the portfolio is most concentrated in Healthcare at 49% of assets, down from 63% a quarter earlier, followed by Consumer Discretionary and Technology.

On the sell side, the largest reduction was NVIDIA, an estimated $37M trimmed.

  • Artal Group's largest Q3 2019 buy was Global Blood Therapeutics, Inc.: 350,000 shares worth $17M.
  • Artal Group added most to Morphic Holding, Inc. Common Stock in Q3 2019, an estimated $27.6M increase.
  • Artal Group's biggest Q3 2019 reduction was NVIDIA, cutting an estimated $37M.
  • Artal Group fully exited Huazhu Hotels Group in Q3 2019, selling an estimated $12.7M.
  • Artal Group's ten largest holdings make up 58% of its $2.49B portfolio in Q3 2019.
  • Artal Group opened 16 new positions and closed 17 in Q3 2019.
  • Artal Group's portfolio value rose 0.87% quarter-over-quarter to $2.49B.

Based on Artal Group's 13F filing for Q3 2019, filed 14 Nov 2019.